FDA-Cleared AI Software Targets Streak Artifacts in Cone-Beam CT
The CleaRecon DL software reportedly removes streak artifacts that can occur with the use of cone-beam computed tomography (CBCT) during interventional radiology procedures.
For interventional radiologists, GE HealthCare has unveiled CleaRecon DL, a deep learning software that addresses the challenge of streak artifacts that can hamper cone-beam computed tomography (CBCT) acquisitions during interventional procedures.
Recently cleared by the Food and Drug Administration (FDA), CleaRecon DL removes streak artifacts from CBCT reconstructed images, according to GE HealthCare.
Designed to remove streak artifacts from reconstructed cone-beam CT images, the FDA-cleared CleaRecon DL software reportedly bolsters image quality for interventional radiology procedures involving the prostate, liver, endovascular aortic repair, and neuroradiology applications, according to GE HealthCare, the manufacturer of the software. (Image courtesy of GE HealthCare.)
Employing deep learning algorithms, the company said CleaRecon DL facilitates improved image clarity during interventional radiology procedures involving the liver and prostate as well as neuroradiology applications and procedures involving endovascular aortic repair.
“The introduction of CleaRecon DL represents a leap forward in the interventional suite and for the advancement of CBCT. By improving image quality and reducing artifacts, this technology can empower clinicians to perform procedures with greater precision and confidence,” said Arnaud Marie, General Manager, Interventional Solutions at GE HealthCare.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
